Post hoc analysis reveals high Decipher scores correlate with treatment failure in prostate cancer patients, suggesting potential predictive value for therapy outcomes.
Key Points
High genomic classifier scores independently predict treatment failure in prostate cancer focal therapy.
Patients with GC-high scores had a treatment failure rate of 46% compared to 21% for GC-low scores.
Assessment used multivariable logistic regression to evaluate associations at 6 and 18 months post-treatment.
Findings indicate that a prognostic biomarker may improve management strategies for prostate cancer treatment.